Ozempic maker Novo Nordisk (NVO) is asking the U.S. Food and Drug Administration (FDA) to prohibit compounding pharmacies ...

The FDA said Eli Lilly’s weight-loss drugs were no longer in shortage on Oct. 2, preventing pharmacies from making cheaper ...

Allurion Technologies announced today that it submitted three modules for its weight loss balloon to the FDA for premarket ...

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

Pharmacies currently making copycat versions of Eli Lilly’s tirzepatide face heightened exposure to state enforcement actions ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound were no longer ...

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...

But she also emphasized that GLP-1 medications such as Mounjaro and Ozempic are not the only options when it comes to weight loss or diabetes, and significantly more affordable FDA-approved ...

Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...